🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Singapore / NCT06270459
Recruiting Not applicable

Telerehabilitation Robotics for Upper Limb Rehabilitation After STroke

NCT06270459 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2024-11-01
Last updated
2025-04-11

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

HMAN Robot

HMAN Robot: The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.

Study summary

There has been an observed decrease in motor and functional ability and non-use of the impaired limb in chronic patients. This is due to the immediate drop in intensive daily therapy (5 days per week for 3 hours/day) that is usually provided during the inpatient (acute) phase upon discharge from the hospital.

In this study, the investigators plan to address the low dosage of therapy in the post-acute discharge phase for stroke survivors.

Eligibility

Sex
ALL
Min age
21 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors and CT, CT angiography or MRI brain imaging. 2. Age 21 to 90 years, both males and females. 3. At least \> 28 days post stroke. 4. Upper limb motor impairment of Fugl-Myer Motor Assessment (FMA) scale 10 to 60 5. Has a stable home abode and a carer/ NOK to supervise home based exercise. 6. Ability to sit supported continuously for 60 minutes. 7. Montreal Cognitive Assessment (MOCA) score \> 21/30 8. Able to understand purpose of research and give consent. Exclusion Criteria: 1. Non-stroke related causes of arm motor impairment. 2. Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, end stage renal/liver/heart/lung failure, unresolved cancers. 3. Anticipated life expectancy of \< 6 months. 4. Inability to tolerate sitting continuously for 60 minutes. 5. Local factors potentially worsened by intensive robot-aided arm therapy and computer-based training: active seizures within 3 months, spasticity of Modified Ashworth Scale grades \>2 skin wounds, shoulder, arm pain VAS \> 5/10, active upper limb fractures, arthritis, fixed upper limb flexion contractures. 6. Hemianesthesia of affected limb. 7. History of dementia, severe depression, agitation, or behavioural problems. 8. Pregnancy or lactation in females 9. Absence of reliable carer to provide supervision during home training

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tan Tock Seng Hospital Singapore Singapore Recruiting

More Tan Tock Seng Hospital trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06270459 on ClinicalTrials.gov ↗ ← All trials in Singapore